<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HC438E2D4B386493C9AEF4428B98F33B3" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 421 IH: Allowing Greater Access to Safe and Effective Contraception Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-01-10</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 421</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170110">January 10, 2017</action-date><action-desc><sponsor name-id="L000584">Mrs. Love</sponsor> (for herself, <cosponsor name-id="C001105">Mrs. Comstock</cosponsor>, <cosponsor name-id="S001192">Mr. Stewart</cosponsor>, <cosponsor name-id="C001077">Mr. Coffman</cosponsor>, and <cosponsor name-id="K000378">Mr. Kinzinger</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name>, and in addition to the Committee on <committee-name committee-id="HIF00">Energy and Commerce</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To allow women greater access to safe and effective contraception.</official-title></form>
	<legis-body id="H0C4386985C6647938F2808F3170A5715" style="OLC">
 <section id="HEC95C91166EB41D0AA4F23A79E311E79" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Allowing Greater Access to Safe and Effective Contraception Act</short-title></quote>.</text> </section><section id="H6A1E7586313B4A6B93E23DAC7A388BDE"><enum>2.</enum><header>Applications for non-prescription contraceptive drugs</header> <subsection id="HEEB8721F2A5A42C49C57FCCEBC267B17"><enum>(a)</enum><header>Priority review of application</header><text>The Secretary of Health and Human Services (referred to in this section as the <quote>Secretary</quote>) shall give priority review to any supplemental application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)</external-xref>) for a contraceptive drug, provided that—</text>
 <paragraph id="HEAFA2323A0B74DD9BFBB788AAA1EFC6A"><enum>(1)</enum><text>the supplemental application is with respect to a drug intended for routine use; and</text> </paragraph><paragraph id="H60AE699AC9D6421D8A868B5A45CFC33C"><enum>(2)</enum><text>if the supplemental application is approved, with respect to individuals aged 18 and older, such drug would not be subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353">21 U.S.C. 353(b)(1)</external-xref>).</text>
 </paragraph></subsection><subsection id="H94089A5511D7495C9D36DFA866C5C3BB"><enum>(b)</enum><header>Fee waiver</header><text>The Secretary shall waive the fee under section 736(a)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(a)(1)</external-xref>) with respect to a supplemental application that receives priority review under subsection (a).</text>
 </subsection><subsection id="H81E28695FA5C4A8AB824E892ADECDB8A"><enum>(c)</enum><header>Over-the-Counter availability</header><text>Notwithstanding any other provision of law, with respect to individuals under age 18, a contraceptive drug that is eligible for priority review under subsection (a) shall be subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353">21 U.S.C. 353(b)(1)</external-xref>).</text>
			</subsection></section><section id="H2DF3560C48B5438DB063CF5AD7FBFA92"><enum>3.</enum><header>Empowering women to make their own health decisions</header>
 <subsection id="HBF6FA0C80982449D8C08B54F7F44E538"><enum>(a)</enum><header>No limitations based on whether a drug is prescribed</header><text>Section 9003 of the Patient Protection and Affordable Care Act (<external-xref legal-doc="public-law" parsable-cite="pl/111/148">Public Law 111–148</external-xref>), and the amendments made by such section, are repealed, and the Internal Revenue Code of 1986 shall be applied as if such section, and amendments, had never been enacted.</text>
 </subsection><subsection id="H180AC97DE61244A6837819EE415E9EC6"><enum>(b)</enum><header>No limitations on health FSAs</header><text>Sections 9005 and 10902 of the Patient Protection and Affordable Care Act (<external-xref legal-doc="public-law" parsable-cite="pl/111/148">Public Law 111–148</external-xref>) and section 1403 of the Health Care and Education Reconciliation Act of 2010 (<external-xref legal-doc="public-law" parsable-cite="pl/111/152">Public Law 111–152</external-xref>), and the amendments made by such sections, are repealed, and the Internal Revenue Code of 1986 shall be applied as if such sections, and amendments, had never been enacted.</text>
			</subsection></section></legis-body></bill>


